This is consistent with mTOR being downstream of vascular endothelial growth factor (VEGF) receptors, which are targeted by broad-spectrum receptor tyrosine kinase inhibitors, and which are known oncogenic drivers in PEL and KS. Here, MTOR is linked to Kaposi's sarcoma.